screening of diseases dr zhian s ramzi screening 1 dr. zhian s ramzi
TRANSCRIPT
Screening of diseases
Dr Zhian S Ramzi
Screening 1Dr. Zhian S Ramzi
Screening 2
Screening
• Definition: Presumptive identification of an unrecognized disease or defect by the application of tests, examinations, or other procedures. Classifies asymptomatic people as likely or unlikely to have a disease or defect. Usually not diagnostic.
Dr. Zhian S Ramzi
Screening 3
Screening 4
Screening
Purpose:
Delay onset of symptomatic or clinical disease. Improve survival.
Dr. Zhian S Ramzi
Screening 5
Screening
Seems simple but is complex. There are hidden costs and risks. Screening can create morbidity and anxiety. Must be aware of biases.
Dr. Zhian S Ramzi
Screening 6
Screening
For screening to be successful you need a:
–Suitable disease
–Suitable test
–Suitable screening programDr. Zhian S Ramzi
Screening 7
Suitable Disease
• Has serious consequences
• Is progressive
• Disease treatment must be effective at an earlier stage
• Prevalence of the detectable pre-clinical phase must be high
• Examples of suitable diseases: breast cancer, cervical cancer, hypertension
Dr. Zhian S Ramzi
Screening 8
Suitable Test
• Ideally, it's inexpensive, easy to administer, has minimal discomfort has high level of validity and reliability
• Valid Test: Does what it's supposed to do, that is, correctly classify people with pre-clinical disease as positive and people without pre-clinical disease as negative
Dr. Zhian S Ramzi
Screening 9
Suitable Test
• Reliable Test: Gives you same results on repetition
• Validity is more important than reliability
Dr. Zhian S Ramzi
Screening 10
Suitable Test
Yes No Total
Positive a b a + b
Negative c d c + d
Total a + c b + d a + b + c+ d
Disease Status (Truth)
Screening Test Result
Screening 11
Suitable Test
Measures of test validity
Sensitivity - enables you to pick up the cases of disease
Sensitivity = a / a + c = those that test positive / all with disease
Dr. Zhian S Ramzi
Screening 12
Suitable Test
Specificity - enables you to pick out the no diseased people
Specificity = d / b + d = those that test positive / all with disease
Valid test has high sensitivity and specificity
Dr. Zhian S Ramzi
Screening 13
Screening 14
Suitable TestBreast Cancer Screening Program - Heath Insurance Plan
HIP) Women assigned to screening or usual care. Screening consisted of yearly mammogram and physical exam. Five years of follow‑up produced these results:
Confirmed
Not Confirmed
Total
Positive 132 983 1,115
Negative 45 63,650 63,695
Total 177 64,633 64,810
Breast Cancer
ScreeningTest
Result
Screening 15
Suitable Test
Sensitivity = 132/177 = 74.6%
Specificity = 63,650/64,633 = 98.5%
• Interpretation: The screening was very good at picking out the women who did not have cancer (see specificity) but it missed 25% of the women who did have cancer (see sensitivity).
Dr. Zhian S Ramzi
Screening 16
Suitable Test
• To measure sensitivity and specificity you can wait for disease to develop (as in this example) or you can measure the results of the screening test against the outcome of another screening or diagnostic test (the Gold Standard).
Dr. Zhian S Ramzi
Screening 17
Suitable Test
Criterion of Positivity ‑ test value at which the screening test outcome is considered positive
Test Result
Clearly Negative Grey Zone Clearly Positive
-------------------------??????????????????---------------------
A B C
Criterion of positivity affects sensitivity and specificity. Must trade off between the two.
Dr. Zhian S Ramzi
True Disease Status
Screening Test
Positive Negative Total
Positive True Positives
(TP)
False Positives
(FP)
TP+FP
Negative False Negatives
(FN)
True Negatives
(TN)
FN+TN
Total TP+FN FP+TN TP+FP+FN+TN
Outcomes of a Screening Test
18 Dr. Zhian S Ramzi
Screening 19
Suitable Test
• What are the sensitivity and specificity if A (or B or C) is used as the cutoff for a positive result?
• If criterion is low (Point A) then sensitivity is good but specificity suffers. If criterion is high (Point C) then specificity is good but sensitivity suffers.
• Decisions about criterion of positivity involves weighing the cost of false positives against the cost of false negatives.
Dr. Zhian S Ramzi
Consider:
-The impact of high number of false positives: anxiety, cost of further testing
-Importance of not missing a case: seriousness of disease, likelihood of re-screening
Where do we set the cut-off for a screening test?
Screening 20
Screening 21
Suitable Screening Program
• Definition of a screening program: Application of a specific test in a specific population for a specific disease
• You want to determine if screening program is successful. Does it reduce morbidity and mortality? How to evaluate?
– Feasibility Measures
– Effectiveness Measures
Dr. Zhian S Ramzi
Evaluation of Screening Program
Feasibility Measures Acceptability, cost, predictive value of a positive
test (PV+), predictive value of a negative test (PV-)
Disease
Yes
Status
No
Total
Screening
Test
Positive a b a + b
Result Negative c d c + d
Total a + c b + d a + b + c + d
Screening 22
Screening 23
Evaluation of Screening Program
Dr. Zhian S Ramzi
Evaluation of Screening Program
Breast Cancer Screening Program of HIP
Cancer Confirmed
Cancer Not Confirmed
Total
Positive 132 983 1,115
Negative 45 63,650 63,695
Total 177 64,633 64,810
Breast Cancer
Screening Test
PV+ = 132/1115 = 11.8%PV- = 63,650/63,695 = 99.9%
Screening 24
Screening 25
Evaluation of Screening Program
• PV will increase when sensitivity, specificity, and disease prevalence increases.
• For example, PV+ will increase if you perform breast cancer screening on higher risk population (i.e. women with a family history of breast cancer)
Dr. Zhian S Ramzi
Screening 26
Demonstration of how prevalence effects PV
Use screening test with 99.9% sensitivity and 99.9% specificity in two populations:
• Population A: 1,000 people with low prevalence of disease (1/1,000)
• Two positive results. One will be true positive. One will be a test error. PV+ is 50%
Dr. Zhian S Ramzi
Screening 27
Demonstration of how prevalence effects PV
Use screening test with 99.9% sensitivity and 99.9% specificity in two populations:
• Population B: 1,000 people with high prevalence of disease (10/1,000)
• Eleven positive test results. 10 will be true positives. One will be a test error. PV+ is 10/11 or 90.9%
Dr. Zhian S Ramzi
Screening 28
Evaluation of Screening Program
• Efficacy measures of evaluation
• Want to reduce morbidity and mortality
• For chronic diseases you can assess effectiveness by examining severity of disease at diagnosis, cause-specific mortality rate among people picked up by screening versus people picked up by routine care.
Dr. Zhian S Ramzi
Screening 29
Summary of Screening
• Screening is the presumptive identification of unrecognized disease by the application of tests, exams, etc.
• Suitable disease must be serious with important consequences and progressive
Dr. Zhian S Ramzi
Screening 30
Summary of Screening (cont’d)
• Suitable test must have low cost, be acceptable, and have a high degree of validity
• Validity is measured by sensitivity and specificity
Dr. Zhian S Ramzi
Screening 31
Summary of Screening (cont’d)
• Screening programs administer screening tests in particular populations
• Programs are evaluated mainly by examining predictive value and outcome measures such as stage distribution and cause-specific mortality
• Evaluation must consider lead-time bias, length-biased sampling, and volunteer bias.
Dr. Zhian S Ramzi
Screening 32Dr. Zhian S Ramzi
Dr. Zhian S RamziScreening 33
Screening 34
Natural History of Disease
20 30 40 50 60 70 Years
A B C D
Biological Disease Symptoms Death
Onset Detectable Develop
By Screening
Dr. Zhian S Ramzi
Screening 35
Natural History of Disease
• Total pre-clinical phase = A to C (Age 30 to Age 60) = 30 years
• Detectable pre-clinical phase (DPCP) = B to C (Age 45 to Age 60) = 15 years
Dr. Zhian S Ramzi
Screening 36
Natural History of Disease
• DPCP varies with the test, the disease, and the individual
• Lead Time: Duration of time by which the diagnosis is advanced as a result of screening. B to C (Age 45 to Age 60) = 15 years
Dr. Zhian S Ramzi